Switch to: References

Add citations

You must login to add citations.
  1. The Psychological Process Underlying Attitudes Toward Human-Animal Chimeric Brain Research: An Empirical Investigation.Tetsushi Tanibe, Takumi Watanabe, Mineki Oguchi, Kazuki Iijima & Koji Ota - 2024 - Neuroethics 17 (1):1-19.
    This study adopted an empirical method to investigate lay people’s attitudes toward the bioethical issues of human-animal chimeric brains. The results of online surveys showed that (1) people did not entirely reject chimeric brain research, but showed slightly more negative responses than ordinary animal testing; and that (2) their ethical concerns arose in connection with the perception that chimerism in the brain would humanize the animal. This means that people’s psychology was consistent with the ethical argument that crossing the human-animal (...)
    Download  
     
    Export citation  
     
    Bookmark  
  • The other woman: Evaluating the language of ‘three parent’ embryos.David Albert Jones - 2015 - Clinical Ethics 10 (4):97-106.
    The British Parliament has recently approved regulations to allow techniques ‘to prevent the transmission of serious mitochondrial disease from a mother to her child’. The regulations term these techniques ‘mitochondrial donation’, but in the popular media, the issue has been discussed under the heading of ‘three parent’ babies or ‘three parent’ embryos. This paper examines the language of the debate, with particular reference to one of the techniques approved. It concludes that the terminology of ‘mitochondrial donation’ is scientifically inaccurate and (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • “You are our only hope”: Trading metaphorical “magic bullets” for stem cell “superheroes”.Lawrence Burns - 2009 - Theoretical Medicine and Bioethics 30 (6):427-442.
    In the wake of two recent developments in stem cell research, it is a fitting time to reassess the claim that stem cells will radically transform the concept and function of medicine. The first is the U.S. Food and Drug Administration’s decision in January 2009 to approve Geron Corporation’s Phase I clinical trial using human embryonic stem cells for patients with spinal cord injuries. The second is the National Institutes of Health’s decision to permit federal funding of research using donated (...)
    Download  
     
    Export citation  
     
    Bookmark